DrugPatentWatch Database Preview
XIIDRA Drug Profile
When do Xiidra patents expire, and what generic alternatives are available?
Xiidra is a drug marketed by Shire Dev Llc and is included in one NDA. There are fifteen patents protecting this drug.
This drug has one hundred and three patent family members in twenty-one countries.
The generic ingredient in XIIDRA is lifitegrast. One supplier is listed for this compound. Additional details are available on the lifitegrast profile page.
Summary for XIIDRA
| International Patents: | 103 |
| US Patents: | 15 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 23 |
| Clinical Trials: | 3 |
| Patent Applications: | 51 |
| Drug Prices: | Drug price information for XIIDRA |
| DailyMed Link: | XIIDRA at DailyMed |
Generic Entry Opportunity Date for XIIDRA
Generic Entry Date for XIIDRA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION/DROPS;OPHTHALMIC |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for XIIDRA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Shire Human Genetic Therapies, Inc. | Phase 4 |
| Weill Medical College of Cornell University | Phase 4 |
| Shire | Phase 4 |
Pharmacology for XIIDRA
| Drug Class | Lymphocyte Function-Associated Antigen-1 Antagonist |
| Mechanism of Action | Lymphocyte Function-Associated Antigen-1 Antagonists |
Synonyms for XIIDRA
| (2S)-2-(((2-(Benzofuran-6-ylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinolin-6- yl)carbonyl)amino)-3-(3-(methylsulfonyl)phenyl)propanoic acid |
| (2S)-2-[[2-(1-benzofuran-6-carbonyl)-5,7-dichloro3,4-dihydro-1H-isoquinoline-6-carbonyl]amino]-3-(3-methylsulfonylphenyl)propanoic acid |
| (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid |
| 038E5L962W |
| 1025967-78-5 |
| 1356856-75-1 |
| 915397-62-5 |
| AKOS030628489 |
| BDBM50386331 |
| CHEBI:133023 |
| CHEMBL2048028 |
| compound 1g [PMID: 24900456] |
| CS-6264 |
| D10374 |
| DB11611 |
| DS-20052 |
| DTXSID60145345 |
| EX-A2582 |
| GTPL7533 |
| HY-19344 |
| L-Phenylalanine, N-((2-(6-benzofuranylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydro-6-isoquinolinyl)carbonyl)-3-(methylsulfonyl)- |
| Lifitegrast |
| Lifitegrast (USAN/INN) |
| Lifitegrast [USAN:INN] |
| Lifitegrast; SAR 1118 |
| MolPort-044-727-763 |
| N-[2-(1-benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carbonyl]-3-(methanesulfonyl)-L-phenylalanine |
| SAR 1118 |
| SAR-1118 |
| SAR1118 |
| SB18920 |
| SCHEMBL2632068 |
| UNII-038E5L962W |
| Xiidra (TN) |
| ZINC84668739 |
US Patents and Regulatory Information for XIIDRA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shire Dev Llc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | RX | Yes | Yes | See Pricing | See Pricing | Y | Y | See Pricing | ||
| Shire Dev Llc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | RX | Yes | Yes | See Pricing | See Pricing | Y | See Pricing | |||
| Shire Dev Llc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | RX | Yes | Yes | See Pricing | See Pricing | See Pricing | ||||
| Shire Dev Llc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | RX | Yes | Yes | See Pricing | See Pricing | Y | See Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for XIIDRA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2015523398 | See Pricing |
| South Korea | 20150067129 | See Pricing |
| Japan | 2013010778 | See Pricing |
| Spain | 2383525 | See Pricing |
| >Country | >Patent Number | >Estimated Expiration |
